For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to approvals.

A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis after a brief course, signaling a new era of durable treatment.

NEW YORK – An autologous CAR T-cell therapy has shown promise treating a rare autoimmune disease known as autoimmune hemolytic anemia (AIHA), and plans for evaluations in larger clinical trials are ...

Type 1 diabetes (T1D) is driven by a breakdown of immune tolerance that enables autoreactive T cells to destroy insulin-producing β cells. Although genetic susceptibility is well established, it is ...